

# Brigette

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9480289/brigette-publications-by-year.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

192 papers	11,051 citations	50 h-index	102 g-index
228 ext. papers	13,152 ext. citations	5.1 avg, IF	5.76 L-index

#	Paper	IF	Citations
192	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 840-859	2.2	42
191	Dynamic Changes of Post-Radiotherapy Plasma Epstein-Barr Virus DNA in a Randomized Trial of Adjuvant Chemotherapy Versus Observation in Nasopharyngeal Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2827-2836	12.9	2
190	Nasopharyngeal carcinoma: an evolving paradigm. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> , 18, 679-695	19.4	28
189	Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF- $\kappa$ B activation and immune escape. <i>Nature Communications</i> , <b>2021</b> , 12, 4193	17.4	10
188	Real-World Treatment and Outcomes of Metastatic Colorectal Cancer Patients With a Poor or Very Poor Performance Status. <i>Clinical Colorectal Cancer</i> , <b>2021</b> , 20, e21-e34	3.8	0
187	Convolutional neural network for discriminating nasopharyngeal carcinoma and benign hyperplasia on MRI. <i>European Radiology</i> , <b>2021</b> , 31, 3856-3863	8	7
186	Overcoming the impact of the COVID-19 pandemic on oncology early phase trials and drug development in Asia-Experiences and perspectives of the Asian Oncology Early Phase 1 Consortium. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2021</b> , 17, 388-395	1.9	0
185	Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma. <i>Oral Oncology</i> , <b>2021</b> , 113, 105127	4.4	7
184	BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?. <i>Targeted Oncology</i> , <b>2021</b> , 16, 227-236	5	2
183	Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 6413-6423	12.9	11
182	The expanding universe of checkpoint inhibitors for nasopharyngeal cancer. <i>Nature Medicine</i> , <b>2021</b> , 27, 1512-1513	50.5	2
181	Pre-treatment intravoxel incoherent motion diffusion-weighted imaging predicts treatment outcome in nasopharyngeal carcinoma. <i>European Journal of Radiology</i> , <b>2020</b> , 129, 109127	4.7	7
180	Sequencing Analysis of Plasma Epstein-Barr Virus DNA Reveals Nasopharyngeal Carcinoma-Associated Single Nucleotide Variant Profiles. <i>Clinical Chemistry</i> , <b>2020</b> , 66, 598-605	5.5	5
179	Recent Advances in the Development of Biomarkers and Chemoradiotherapeutic Approaches for Nasopharyngeal Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2020</b> , 40, 1-11	7.1	2
178	Pre-treatment amide proton transfer imaging predicts treatment outcome in nasopharyngeal carcinoma. <i>European Radiology</i> , <b>2020</b> , 30, 6339-6347	8	9
177	Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. <i>Annals of Oncology</i> , <b>2020</b> , 31, 769-779	10.3	27
176	Early Detection of Cancer: Evaluation of MR Imaging Grading Systems in Patients with Suspected Nasopharyngeal Carcinoma. <i>American Journal of Neuroradiology</i> , <b>2020</b> , 41, 515-521	4.4	10

175	The emerging data on choice of optimal therapy for locally advanced nasopharyngeal carcinoma. <i>Current Opinion in Oncology</i> , <b>2020</b> , 32, 187-195	4.2	6
174	Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts. <i>Cancer Science</i> , <b>2020</b> , 111, 536-547	6.9	24
173	Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR, HER2 Advanced Breast Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6417-6428	12.9	5
172	Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 1307-1316	4	4
171	Quantitative T1-MRI of the Head and Neck Discriminates Carcinoma and Benign Hyperplasia in the Nasopharynx. <i>American Journal of Neuroradiology</i> , <b>2020</b> , 41, 2339-2344	4.4	1
170	Complementary roles of MRI and endoscopic examination in the early detection of nasopharyngeal carcinoma. <i>Annals of Oncology</i> , <b>2019</b> , 30, 977-982	10.3	29
169	Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2019</b> , 15, 225-230	1.9	3
168	Distinguishing early-stage nasopharyngeal carcinoma from benign hyperplasia using intravoxel incoherent motion diffusion-weighted MRI. <i>European Radiology</i> , <b>2019</b> , 29, 5627-5634	8	21
167	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 655-663	9.7	35
166	Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. <i>Genome Research</i> , <b>2019</b> , 29, 418-427	9.7	81
165	Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases. <i>Nature Communications</i> , <b>2019</b> , 10, 3256	17.4	30
164	Abstract CT150: Phase II study of spartalizumab (PDR001) vs chemotherapy (CT) in patients with recurrent/metastatic nasopharyngeal cancer (NPC) <b>2019</b> ,		12
163	Development and validation of a risk model integrating plasma Epstein-Barr virus DNA (EBV DNA) level and TNM stage for stratification of nasopharyngeal cancer (NPC) to adjuvant therapy. <i>Annals of Oncology</i> , <b>2019</b> , 30, ix97-ix98	10.3	2
162	Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?. <i>Internal Medicine Journal</i> , <b>2019</b> , 49, 446-454	1.6	5
161	Extranodal extension is a criterion for poor outcome in patients with metastatic nodes from cancer of the nasopharynx. <i>Oral Oncology</i> , <b>2019</b> , 88, 124-130	4.4	23
160	Amide proton transfer MRI detects early changes in nasopharyngeal carcinoma: providing a potential imaging marker for treatment response. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2019</b> , 276, 505-512	3.5	9
159	Staging nodal metastases in nasopharyngeal carcinoma: which method should be used to measure nodal dimension on MRI?. <i>Clinical Radiology</i> , <b>2018</b> , 73, 640-646	2.9	11
158	Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1824-1833	12.9	78

157	Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1030-1037	12.9	26
156	Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1051-1055	8.7	13
155	The Effect of Centrifugal Force in Quantification of Colorectal Cancer-Related mRNA in Plasma Using Targeted Sequencing. <i>Frontiers in Genetics</i> , <b>2018</b> , 9, 165	4.5	6
154	Epstein-Barr Virus-Induced Epigenetic Pathogenesis of Viral-Associated Lymphoepithelioma-Like Carcinomas and Natural Killer/T-Cell Lymphomas. <i>Pathogens</i> , <b>2018</b> , 7,	4.5	11
153	Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study. <i>Future Oncology</i> , <b>2018</b> , 14, 2031-2044	3.6	11
152	Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, e593-e599	3.8	6
151	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 1239-1249	5.5	47
150	Head and Neck Tumors: Amide Proton Transfer MRI. <i>Radiology</i> , <b>2018</b> , 288, 782-790	20.5	29
149	Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer. <i>Oncologist</i> , <b>2018</b> , 23, 1436-1445	5.7	4
148	Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3534-3534	2.2	1
147	Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab + first-line (1L) FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 747-747	2.2	1
146	Abstract CT069: Baseline gene expression patterns of CDK4/6 inhibitor-naïve or -refractory HR+, HER2- advanced breast cancer in the phase Ib study of ribociclib plus everolimus plus exemestane <b>2018</b> ,		2
145	Nasopharyngeal carcinoma: relationship between invasion of the prevertebral space and distant metastases. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2018</b> , 275, 497-505	3.5	6
144	MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, S407	8.9	15
143	Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1412-1418	2.2	185
142	Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , JCO2018777847	2.2	90
141	Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma. <i>Scientific Reports</i> , <b>2018</b> , 8, 8010	4.9	18
140	Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E5115-E5124	11.5	75

139	Exome and genome sequencing of nasopharynx cancer identifies NF- $\kappa$ B pathway activating mutations. <i>Nature Communications</i> , <b>2017</b> , 8, 14121	17.4	163
138	Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data. <i>BMC Cancer</i> , <b>2017</b> , 17, 8	4.8	25
137	Prediction of distant metastases from nasopharyngeal carcinoma: Improved diagnostic performance of MRI using nodal volume in N1 and N2 stage disease. <i>Oral Oncology</i> , <b>2017</b> , 69, 74-79	4.4	16
136	Investigational drugs for nasopharyngeal carcinoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 677-685	5.9	15
135	Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1576-1581	10.3	15
134	Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 513-522	59.2	338
133	Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. <i>Clinical Colorectal Cancer</i> , <b>2017</b> , 16, e73-e88	3.8	10
132	Diffusion-weighted imaging of nasopharyngeal carcinoma to predict distant metastases. <i>European Archives of Oto-Rhino-Laryngology</i> , <b>2017</b> , 274, 1045-1051	3.5	10
131	Abstract CT076: Multicenter phase II study of nivolumab in previously treated patients with recurrent and metastatic non-keratinizing nasopharyngeal carcinoma - Mayo clinic Phase 2 Consortium P2C-MN026, NCI9742, NCT02339558 <b>2017</b> ,		2
130	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 6002-6002	2.2	8
129	An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 1255-61	5.5	9
128	441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC. <i>Annals of Oncology</i> , <b>2016</b> , 27,	10.3	28
127	Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. <i>Oncologist</i> , <b>2016</b> , 21, 292-300	5.7	28
126	Abstract P6-13-01: Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2 $\neg$ advanced breast cancer <b>2016</b> ,		14
125	The association between serum folate level and toxicity of capecitabine.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3566-3566	2.2	1
124	Clinical outcome of neoadjuvant chemoradiation in locally advanced rectal cancer at a tertiary hospital. <i>Hong Kong Medical Journal</i> , <b>2016</b> , 22, 546-55	0.7	1
123	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1386-422	10.3	1683
122	Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors. <i>Cancer Science</i> , <b>2016</b> , 107, 1477-1483	6.9	15

121	Jagged 2 silencing inhibits motility and invasiveness of colorectal cancer cell lines. <i>Oncology Letters</i> , <b>2016</b> , 12, 5193-5198	2.6	6
120	Diffusion-Weighted Imaging of Nasopharyngeal Carcinoma: Can Pretreatment DWI Predict Local Failure Based on Long-Term Outcome?. <i>American Journal of Neuroradiology</i> , <b>2016</b> , 37, 1706-12	4.4	22
119	Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3356-64	2.2	410
118	Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). <i>Investigational New Drugs</i> , <b>2015</b> , 33, 985-91	4.3	20
117	Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. <i>Investigational New Drugs</i> , <b>2015</b> , 33, 942-53	4.3	20
116	Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. <i>Cancer</i> , <b>2015</b> , 121, 2720-9	6.4	34
115	Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2015</b> , 11, 160-9	1.9	11
114	Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 619-29	21.7	428
113	Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. <i>BMC Cancer</i> , <b>2015</b> , 15, 395	4.8	72
112	A phase II study of axitinib in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 6031-6031	2.2	2
111	Effects of regorafenib therapy on health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) in the phase III CONCUR trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 697-697	2.2	1
110	Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 566-566	2.2	
109	Regional variation in physicians' awareness, understanding, and use of personalized medicine in the treatment of cancer and perception of patient (pt) education.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 574-574	2.2	
108	Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1204-8	10.3	138
107	The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation. <i>Molecular Cancer Research</i> , <b>2014</b> , 12, 228-38	6.6	53
106	Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus. <i>Clinical Colorectal Cancer</i> , <b>2014</b> , 13, 145-55	3.8	14
105	Current and future molecular diagnostics in colorectal cancer and colorectal adenoma. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 3847-57	5.6	27
104	Colorectal cancer in Chinese patients: current and emerging treatment options. <i>OncoTargets and Therapy</i> , <b>2014</b> , 7, 1817-28	4.4	24



103	Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. <i>Radiology</i> , <b>2014</b> , 270, 607-20	20.5	31
102	500 Triple blockade with LEE011, everolimus, and exemestane in women with ER+/HER2- advanced/metastatic breast cancer: results from a Phase Ib clinical trial. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 163	7.5	3
101	Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. <i>Cancer Biology and Therapy</i> , <b>2014</b> , 15, 768-76	4.6	47
100	An update on the safety and efficacy of regorafenib in the treatment of solid cancers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2014</b> , 10, 1607-14	5.5	8
99	Personalizing therapy for colorectal cancer. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 139-44	6.9	21
98	Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models. <i>Cancer Letters</i> , <b>2014</b> , 343, 24-32	9.9	25
97	Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2520-2520	2.2	27
96	Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6029-6029	2.2	1
95	Identifying an early indicator of drug efficacy in patients (pts) with metastatic colorectal cancer (mCRC): A prospective evaluation of circulating tumor cells (CTC), 18F-fluorodeoxyglucose positron-emission tomography (PET), and the RECIST criteria.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3582-3582	2.2	
94	A joint United Kingdom (UK) and Hong Kong (HK) study to determine prognostic factors for hepatocellular carcinoma (HCC) undergoing curative and palliative treatment.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 181-181	2.2	
93	Predictive factors for overall quality of life in patients with advanced cancer. <i>Supportive Care in Cancer</i> , <b>2013</b> , 21, 1709-16	3.9	46
92	Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 1417-25	3.5	12
91	Preclinical evaluation of the PI3K-mTOR dual inhibitor PF-04691502 as a novel therapeutic drug in nasopharyngeal carcinoma. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 1399-408	4.3	21
90	Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 567-75	4.3	31
89	Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 30-8	4.3	8
88	Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. <i>Cancer Research</i> , <b>2013</b> , 73, 1676-88	10.1	127
87	Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 18761-8	11.5	267
86	Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. <i>Cancer</i> , <b>2013</b> , 119, 4145-53	6.4	9

85	Advanced technologies for studying circulating tumor cells at the protein level. <i>Expert Review of Proteomics</i> , <b>2013</b> , 10, 579-89	4.2	3
84	Clinical significance of frizzled homolog 3 protein in colorectal cancer patients. <i>PLoS ONE</i> , <b>2013</b> , 8, e79481	3.7	19
83	Randomized phase II study of erlotinib (ERL) in two different schedules with concomitant modifiedXELOX in the first-line treatment of metastatic colorectal cancer (mCRC): Correlation with serial serum levels of amphiregulin (AMR) and transforming growth factor receptor-alpha (TGFA).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 425-425	2.2	
82	Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e14501-e14501	2.2	
81	Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 104, 300-4	5.3	68
80	Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3341-7	2.2	146
79	Dynamic contrast enhancement magnetic resonance imaging (DCE-MRI) for differential diagnosis in head and neck cancers. <i>European Journal of Radiology</i> , <b>2012</b> , 81, 784-8	4.7	56
78	Novel systemic therapeutic for nasopharyngeal carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , <b>2012</b> , 16 Suppl 1, S63-8	6.4	18
77	A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma. <i>Cancer</i> , <b>2012</b> , 118, 3984-92	6.4	43
76	Management of hepatocellular carcinoma: beyond sorafenib. <i>Current Oncology Reports</i> , <b>2012</b> , 14, 257-66	6.3	22
75	A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. <i>Annals of Oncology</i> , <b>2012</b> , 23, 1287-1292	10.3	91
74	Abstract 4602: Preclinical evaluation of the AKT inhibitor MK2206 in nasopharyngeal carcinoma cell lines <b>2012</b> ,		2
73	A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiotherapy (CRT).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 5511-5511	2.2	4
72	Radiation injury of the parotid glands during treatment for head and neck cancer: assessment using dynamic contrast-enhanced MR imaging. <i>Radiation Research</i> , <b>2011</b> , 175, 291-6	3.1	24
71	Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26, 340-7	4	64
70	Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients. <i>British Journal of Cancer</i> , <b>2011</b> , 104, 1000-6	8.7	18
69	Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma. <i>Investigational New Drugs</i> , <b>2011</b> , 29, 1123-31	4.3	25
68	Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. <i>Supportive Care in Cancer</i> , <b>2011</b> , 19, 1625-35	3.9	32



67	Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1280-1287	10.3	77
66	A phase I trial of recombinant modified vaccinia ankara (MVA) vaccine encoding Epstein-Barr virus (EBV) antigens.. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 2592-2592	2.2	2
65	Population-based differences in treatment outcome following anticancer drug therapies. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 75-84	21.7	110
64	Personalized cancer therapy coming of age: clinical highlights in 2009 and future directions. <i>Personalized Medicine</i> , <b>2010</b> , 7, 121-124	2.2	2
63	The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. <i>Investigational New Drugs</i> , <b>2010</b> , 28, 107-14	4.3	52
62	The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. <i>Investigational New Drugs</i> , <b>2010</b> , 28, 413-20	4.3	55
61	Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response. <i>Investigational New Drugs</i> , <b>2010</b> , 28, 326-33	4.3	32
60	Long-term treatment outcome of nasopharyngeal carcinoma (NPC) using intensity-modulated radiotherapy (IMRT).. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 5582-5582	2.2	2
59	Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer. <i>Journal of Oncology</i> , <b>2009</b> , 2009, 967920	4.5	6
58	Update on Anti-EGFR Therapy. <i>Journal of Oncology</i> , <b>2009</b> , 2009, 157964	4.5	1
57	Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 1005-12	12.9	56
56	Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 242-9	2.2	405
55	New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 446-52	2.2	205
54	Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms. <i>Annals of Oncology</i> , <b>2009</b> , 20, 1854-9	10.3	47
53	STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. <i>International Journal of Cancer</i> , <b>2009</b> , 125, 1884-93	7.5	58
52	The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 1146-1152	7.5	86
51	Advanced proteomic technologies for cancer biomarker discovery. <i>Expert Review of Proteomics</i> , <b>2009</b> , 6, 123-34	4.2	49
50	Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions. <i>Cancer Science</i> , <b>2008</b> , 99, 1311-8	6.9	96

49	The prognostic significance of tumor vascular invasion and its association with plasma Epstein-Barr virus DNA, tumor volume and metabolic activity in locoregionally advanced nasopharyngeal carcinoma. <i>Oral Oncology</i> , <b>2008</b> , 44, 1067-72	4.4	17
48	Update on the management and therapeutic monitoring of advanced nasopharyngeal cancer. <i>Hematology/Oncology Clinics of North America</i> , <b>2008</b> , 22, 1267-78, x	3.1	56
47	Isolated tumor cells and circulating CK20 mRNA in pN0 colorectal cancer patients. <i>International Journal of Surgical Pathology</i> , <b>2008</b> , 16, 119-26	1.2	14
46	The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. <i>British Journal of Radiology</i> , <b>2008</b> , 81, 291-8	3.4	67
45	A novel application of plasma and cerebrospinal fluid level of epstein barr virus DNA in the diagnosis of leptomeningeal metastasis from nasopharyngeal carcinoma. A case report. <i>Oncology</i> , <b>2008</b> , 74, 119-22	3.6	2
44	Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 7080-7	12.9	31
43	Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. <i>Oncology Reports</i> , <b>2008</b> ,	3.5	7
42	A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. <i>Investigational New Drugs</i> , <b>2008</b> , 26, 169-73	4.3	123
41	A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 62, 59-64	3.5	67
40	Therapeutic vaccination with modified vaccinia Ankara (MVA) encoding Epstein-Barr virus (EBV) target antigens in EBV+ nasopharyngeal carcinoma (NPC). <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3052-3052	2.2	2
39	A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy (IMRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) with correlation using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 6055-6055	2.2	10
38	Adjuvant chemoradiation for gastric cancer: experience in the Chinese population. <i>Clinical Oncology</i> , <b>2007</b> , 19, 333-40	2.8	9
37	Nasopharyngeal cancers: which method should be used to measure these irregularly shaped tumors on cross-sectional imaging?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2007</b> , 69, 148-54	4	25
36	Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. <i>Oncogene</i> , <b>2007</b> , 26, 7490-8	9.2	91
35	Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma--a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor. <i>Oral Oncology</i> , <b>2007</b> , 43, 373-8	4.4	23
34	The effect of centrifugation on circulating mRNA quantitation opens up a new scenario in expression profiling from patients with metastatic colorectal cancer. <i>Clinical Biochemistry</i> , <b>2007</b> , 40, 1277-84	3.5	6
33	Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2007</b> , 59, 295-300	3.5	13
32	Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. <i>Cancer Letters</i> , <b>2007</b> , 253, 74-88	9.9	46

31	Efficacy of neoadjuvant docetaxel and cisplatin followed by concurrent cisplatin-radiotherapy in locally advanced nasopharyngeal carcinoma (NPC): A randomized phase II study. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 6037-6037	2.2	3
30	Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma. <i>BMC Cancer</i> , <b>2006</b> , 6, 259	4.8	6
29	Transcriptional profiling of tumor biopsies in oncology trials--a 'window' of opportunity for evaluating new drugs in nasopharyngeal cancer?. <i>Annals of Oncology</i> , <b>2006</b> , 17, 1611-3	10.3	1
28	Radiation-induced spinal glioblastoma multiforme. <i>Acta Oncologica</i> , <b>2006</b> , 45, 87-90	3.2	16
27	Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. <i>Expert Review of Anticancer Therapy</i> , <b>2006</b> , 6, 383-94	3.5	37
26	An unusual cause of superior vena cava obstruction. <i>Thorax</i> , <b>2006</b> , 61, 182	7.3	3
25	Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5414-8	2.2	285
24	Pharmacoproteomics study of cetuximab in nasopharyngeal carcinoma. <i>Journal of Proteome Research</i> , <b>2006</b> , 5, 3260-7	5.6	18
23	Case of chlorambucil-induced seizure. <i>Internal Medicine Journal</i> , <b>2006</b> , 36, 683-4	1.6	2
22	Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 66, 714-20	4	84
21	Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression. <i>Biomedicine and Pharmacotherapy</i> , <b>2005</b> , 59 Suppl 2, S268-71	7.5	14
20	Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. <i>Medical Oncology</i> , <b>2005</b> , 22, 303-12	3.7	49
19	Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. <i>Cancer</i> , <b>2005</b> , 103, 22-31	6.4	100
18	Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 536-9	9.7	371
17	Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3568-76	2.2	233
16	A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 1532-8	9.7	490
15	A randomized phase II study of concurrent cisplatin-radiotherapy (RT) with or without neoadjuvant chemotherapy using docetaxel and cisplatin in advanced nasopharyngeal carcinoma (NPC). <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5544-5544	2.2	1
14	Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. <i>Annals of Oncology</i> , <b>2004</b> , 15, 1661-6	10.3	132

13	Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 3053-60	2.2	103
12	The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. <i>International Journal of Gynecological Cancer</i> , <b>2004</b> , 14, 650-8	3.5	120
11	Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy. <i>Cancer</i> , <b>2004</b> , 101, 776-81	6.4	18
10	Radiotherapy for nasopharyngeal carcinoma--transition from two-dimensional to three-dimensional methods. <i>Radiotherapy and Oncology</i> , <b>2004</b> , 73, 163-72	5.3	53
9	Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 2760-76	2.2	115
8	Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. <i>Cancer</i> , <b>2003</b> , 98, 288-91	6.4	129
7	Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study. <i>Head and Neck</i> , <b>2003</b> , 25, 864-72	4.2	146
6	Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. <i>Cancer</i> , <b>2002</b> , 95, 2516-23	6.4	73
5	Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 1614-9	9.7	315
4	Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer -- a retrospective review of Chinese patients and comparison with an historic Western series. <i>Radiotherapy and Oncology</i> , <b>2002</b> , 62, 185-9	5.3	44
3	Clinical trial designs for targeted agents. <i>Hematology/Oncology Clinics of North America</i> , <b>2002</b> , 16, 1287-305	3.05	12
2	Cure of pulmonary <i>Rhizomucor pusillus</i> infection in a patient with hairy-cell leukemia: role of liposomal amphotericin B and GM-CSF. <i>Leukemia and Lymphoma</i> , <b>2001</b> , 42, 1393-9	1.9	29
1	Combined modality treatment for locally advanced squamous-cell carcinoma of the oropharynx in a woman with Bloom's syndrome: a case report and review of the literature. <i>Annals of Oncology</i> , <b>2001</b> , 12, 1015-7	10.3	11